SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999, to receive the free SmallCapReview newsletter and be entered to win a Free iPod Touch visit http://www.smallcapreview.com/.
ViroPharma Incorporated (Nasdaq: VPHM) $11.39. Today announced its financial results for the second quarter ended June 30, 2010. Achieved a record $109 million in net product sales; Increased Cinryze net sales by 58 percent over prior year's second quarter to $40 million; Attained Non-GAAP adjusted net income of $36 million, representing 38 percent growth over the prior year second quarter; GAAP net income reached $29 million; Delivered record positive cash flows from operations of $54 million; Improved working capital to $465 million as of June 30, 2010, including cash, cash equivalents and short-term investments of $406 million; Submitted the Cinryze industrial scale manufacturing Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration (FDA); Introduced parallel chromatography-produced Cinryze into the trade for sale; Completed Phase 1 study of non-toxigenic C. difficile (VP20621); Initiated Phase 2 study of subcutaneous administration of Cinryze. Net sales were $109.0 million and $199.6 million for the three and six months ended.
What They Do: ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.
Bruker Corporation (Nasdaq: BRKR) $11.39. Today announced financial results for the three and six months ended June 30, 2010. In the second quarter of 2010, revenue was $300.9 million, an increase of 19% compared to revenue of $252.5 million in the second quarter of 2009. Excluding the effects of acquisitions and foreign currency translation, second quarter 2010 revenue increased by 20% year-over-year. GAAP net income for the second quarter of 2010 was $22.6 million, or $0.14 per diluted share, compared to GAAP net income of $12.9 million, or $0.08 per diluted share, in the second quarter of 2009. Adjusted net income for the second quarter of 2010 was $25.0 million, or $0.15 per diluted share, compared to adjusted net income of $12.3 million, or $0.07 per diluted share, in the second quarter of 2009.
What They Do: Bruker Corporation designs and manufactures life science and materials research systems, and related products.
CEVA, Inc. (Nasdaq: CEVA) $13.01. Today announced its financial results for the second quarter ended June 30, 2010. Total revenue for the second quarter of 2010 was $10.6 million, an increase of 16% compared to $9.1 million reported for the second quarter of 2009. Second quarter of 2010 licensing revenue was $4.6 million, an increase of 7% compared to $4.3 million reported for the second quarter of 2009. Royalty revenue for the second quarter of 2010 was a record high $5.2 million, an increase of 30% over $4.0 million reported for the second quarter of 2009. Revenue from services for both the second quarter of 2010 and 2009 was $0.9 million.
U.S. GAAP net income for the second quarter of 2010 was $2.1 million, a decrease of 8% compared to $2.3 million reported for the same period in 2009. U.S. GAAP diluted earnings per share for the second quarter of 2010 was $0.10, a decrease of 17% compared to $0.12 reported for the second quarter of 2009. U.S. GAAP net income for the second quarter of 2009 included a pre-tax capital gain of $1.9 million related to our equity divestment of GloNav, Inc. to NXP Semiconductors.
What They Do: CEVA is the world's leading licensor of silicon intellectual property (SIP) DSP Cores and platform solutions for the mobile handset, portable and consumer electronics markets.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
